ArticleFrontiers in oncology2026
Consolidation cycles, measurable residual disease, and DNMT3A/ASXL1 mutations independently predict relapse-free survival in older adults with acute myeloid leukemia.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Older adults with acute myeloid leukemia (AML) remain prone to relapse despite achieving remission. We retrospectively analyzed 102 consecutive AML patients ≥ 60 years from two centers in Shanxi, China, who attained complete remission (CR/CRi) after induction with either "3 + 7" or venetoclax plus azacitidine (VEN-AZA). Clinical variables, next-generation sequencing, measurable residual disease (MRD) by multiparameter flow cytometry, and consolidation details were evaluated. Median relapse-free survival (RFS) was 9.7 months (95% CI 7.2-12.2). On multivariable analysis, DNMT3A (HR 2.49, p = 0.005) and ASXL1 (HR 2.88, p = 0.016) mutations and MRD positivity (HR 1.95, p = 0.027) predicted inferior RFS, while receiving ≥ 2 consolidation cycles (HR 0.15, p < 0.001) was protective. The induction regimen was not independently significant. In older AML achieving remission, sustained consolidation and MRD-guided surveillance are pivotal, particularly in patients harboring DNMT3A or ASXL1 mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.